

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC. and MYLAN LABORATORIES
LIMITED,
Petitioner

v.

UCB PHARMA GMBH
Patent Owner

Patent No. 6,858,650
Case IPR2016-00510¹

**PETITIONER'S MYLAN PHARMACEUTICALS INC.'S
OPPOSITION TO PATENT OWNER'S MOTION TO EXCLUDE
EVIDENCE**

¹ Petitioner Alembic Pharmaceuticals Limited from IPR2016-01596, Torrent Pharmaceuticals Limited from IPR2016-01636, and Amerigen Pharmaceuticals Limited from IPR2016-01665 have been joined as Petitioners to this proceeding.

TABLE OF CONTENTS

I. Introduction.....1

II. Evidence of Commercial Success Is Relevant To The Asserted
Secondary Considerations Of Long-felt But Unmet Need.....2

 A. Commercial Success Is Relevant Evidence When
 Considering Whether A Unmet Need Has Been Met2

 B. The Lack of Toviaz®’s Commercial Success Is Relevant
 To Demonstrate Toviaz® Has Not Met Any Unmet Need
 In The Marketplace6

III. Exhibits 1050-1072 Should Not Be Expunged8

IV. Conclusion9

TABLE OF AUTHORITY

Cases

<i>ATD Corp. v. Lydall, Inc.</i> , 159 F.3d 534 (Fed. Cir. 1998)	2
<i>Belden Inc. v. Berk-Tek LLC</i> , 805 F.3d 1064 (Fed. Cir. 2015)	8
<i>Brookwood Co. Inc. v. Nextex Applications, Inc.</i> , IPR2014-00412, Paper 19 (PTAB Sept. 24, 2014).....	9
<i>Ethicon Endo-Surgery, Inc. v. Covidien LP</i> , 812 F.3d 1023, 1035 (Fed. Cir. 2016)	5
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , 794 F. Supp. 2d 517 (D. Del. 2011), <i>aff'd in part, vacated in part, rev'd in part on other grounds</i> , 676 F.3d 1063 (Fed. Cir. 2012).....	2, 3
<i>In re Fielder</i> , 471 F.2d 640 (CCPA 1973)	3
<i>In re GPAC Inc.</i> , 57 F.3d 1573 (Fed. Cir. 1988)	4
<i>In re Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	4
<i>In re Tiffin</i> , 448 F.2d 791 (CCPA 1971)	4
<i>McNeil-PPC, Inc. v. L. Perrigo Co.</i> , 337 F.3d 1362 (Fed. Cir. 2003)	6
<i>Merck Sharp & Dohme Corp. v. Hospira Inc.</i> , No. CV 14-915-RGA, 2016 WL 5872620 (D. Del. July 10, 2016)	5
<i>Merck Sharpe & Dohme B.V. v. Warner Chilcott Co.</i> , Case No. CV 13-2088-GMS, 2016 WL 4497054 (D. Del. Aug. 26, 2016)	5

<i>Phigenix, Inc. v. Immunogen, Inc.</i> , IPR2014-00676, Paper 39 (PTAB Oct. 27, 2015).....	8
<i>Samsung Elecs. Co. v. Virginia Innovation Sci., Inc.</i> , IPR2013-00569, Paper 42.....	1
<i>Santarus, Inc. v. Par Pharm., Inc.</i> , 720 F. Supp. 2d 427 (D. Del. 2010) (Sleet, J.) <i>aff'd in part, rev'd in part</i> , 694 F.3d 1344 (Fed. Cir. 2012).....	2, 3
<i>Symantic Corp. v. The Trustees of Columbia University in the City of New York</i> , IPR2015-00372, Paper 30 (PTAB Sept. 29, 2015).....	9
<i>Vanda Pharm. Inc. v. Roxane Labs., Inc.</i> , No. CV 13-1973-GMS, 2016 WL 4490701 (D. Del. Aug. 25, 2016).....	3

Statutes

37 C.F.R. § 42.64(b)(2).....	x
37 C.F.R. § 42.64.....	9
Fed. R. Evid. 611(a).....	8

Other Authorities

Chisum § 5.05[2][a].....	3
--------------------------	---

Rules

“Subtests of ‘Nonobviousness’: A Nontechnical Approach to Patent Validity,” 112 U. Pa. L. Rev. 1169 (1964).....	3
--	---

PETITIONER'S LIST OF EXHIBITS

- Ex. 1001: U.S.P.N. 7,384,980
- Ex. 1002: File History for U.S.P.N. 7,384,980
- Ex. 1003: Declaration of Dr. Steven Patterson, Ph.D.
- Ex. 1004: C.V. for Dr. Steven Patterson, Ph.D
- Ex. 1005: "Johansson" – WO 94/11337 Filed 6 November 1992 – "Novel 3,3-Diphenylpropylamines, Their Use and Preparation"
- Ex. 1006: "Andersson Review" – BJU International (1999), 84, 923-947 – "The Pharmacological Treatment of Urinary Incontinence"; K-E Andersson, R. Appell, L.D. Cardozo, C. Chapple, H.P. Drutz, A.E. Finkbeiner, F. Haab, and R. Vela Navarrete
- Ex. 1007: "Brynne 1997" – International Journal of Clinical Pharmacology and Therapeutics (1997), 35, 287-295 – "Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity"; N. Brynne, M.M.S. Stahl, B. Hallen, P.O. Edlund, L. Palmer, P. Hoglund, and J. Gabrielsson
- Ex. 1008: "Thomas" – British Heart Journal (1995), 74, 53-56 – "Concentration dependent cardiotoxicity of terodine in patients treated for urinary incontinence"; S. Thomas, P. Higham, K Hartigan-Go, F. Kamali, P. Wood, R. Campbell, and G. Ford
- Ex. 1009: "Detrol® Label" – Pharmacia & Upjohn
- Ex. 1010: "Postlind" – Drug Metabolism and Disposition (1998), 26 (4), 289-293 – "Tolterodine, A New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes"; H. Postlind, A. Danielson, A.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.